SEC Company Response from MARRONE BIO INNOVATIONS INC (CIK 0001441693) — Dec 30, 2020

MARRONE BIO INNOVATIONS INC (CIK 0001441693)
Date: Dec. 30, 2020 · CIK: 0001441693 · Accession: 0001493152-20-024514

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-251284

Date

December 11, 2020

Author

Chief

Form

CORRESP

Company

MARRONE BIO INNOVATIONS INC (CIK 0001441693)

Letter

December 30, 2020

VIA EDGAR

Division of Corporation Finance

Office of Life Sciences

United States Securities and Exchange Commission

F Street, NE

Washington, D.C. 20549

Attention: Laura Crotty

Re: Marrone Bio Innovations, Inc.

Registration Statement on Form S-3

Filed on December 11, 2020

File No. 333-251284

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Marrone Bio Innovations, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-251284) to 9:00 a.m., Eastern Time, on January 4, 2021, or as soon as practicable thereafter.

The Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company’s counsel at Morrison & Foerster LLP, at (415) 268-6213 or asilva@mofo.com.

Very
truly yours,
Marrone
Bio Innovations, Inc.

Show Raw Text

CORRESP
1
filename1.htm

December
30, 2020

VIA
EDGAR

Division
of Corporation Finance

Office
of Life Sciences

United
States Securities and Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

Attention:
Laura Crotty

    Re:
    Marrone
    Bio Innovations, Inc.

    Registration
    Statement on Form S-3

    Filed
    on December 11, 2020

    File
    No. 333-251284

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Marrone Bio Innovations, Inc. (the “Registrant”) hereby
requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-251284) to 9:00 a.m., Eastern Time,
on January 4, 2021, or as soon as practicable thereafter.

The
Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company’s counsel at
Morrison & Foerster LLP, at (415) 268-6213 or asilva@mofo.com.

    Very
    truly yours,

    Marrone
    Bio Innovations, Inc.

    By:
    /s/
    Kevin Helash

    Name:
    Kevin
    Helash

    Title:
    Chief
    Executive Officer

SecProbe.io